Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy
Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs. Patients treated with anti-PD-1 monotherapy or in combination with...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2017-08, Vol.37 (8), p.4229-4232 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4232 |
|---|---|
| container_issue | 8 |
| container_start_page | 4229 |
| container_title | Anticancer research |
| container_volume | 37 |
| creator | Ariyasu, Ryo Horiike, Atsushi Yoshizawa, Takahiro Dotsu, Yosuke Koyama, Junji Saiki, Masafumi Sonoda, Tomoaki Nishikawa, Shingo Kitazono, Satoru Yanagitani, Noriko Nishio, Makoto |
| description | Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs.
Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected.
Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case.
Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms. |
| doi_str_mv | 10.21873/anticanres.11814 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1923115271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1923115271</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-c6218671ec711029717ac76ad3395d53b55256069ada537fa948c7239712e8af3</originalsourceid><addsrcrecordid>eNo1j81OwzAQhC0kREvhAbigHLmkZO3Yjm9UpUClSiBUztHW2dCg_GEnh7w9RpTTSKvZmW8Yu4FkySHT4h7bobLYOvJLgAzSMzYHbSDWUiQzdun9V5IoZTJxwWY8PBgNMGcPq8JRi3W0bf1YlpWtqLVT9E41DlREQxetQm785rpPh00TTo-EwzGGaH8kh_10xc5LrD1dn3TBPp42-_VLvHt93q5Xu7iHFIbYqkCpNJANtQkP5RqtVlgIYWQhxUFKLlWiDBYohS7RpJnV_JeSU4alWLC7v9zedd8j-SFvKm-prrGlbvQ5GC4AJNcQrLcn63gIxHnvqgbdlP-vFj97QVdb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1923115271</pqid></control><display><type>article</type><title>Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ariyasu, Ryo ; Horiike, Atsushi ; Yoshizawa, Takahiro ; Dotsu, Yosuke ; Koyama, Junji ; Saiki, Masafumi ; Sonoda, Tomoaki ; Nishikawa, Shingo ; Kitazono, Satoru ; Yanagitani, Noriko ; Nishio, Makoto</creator><creatorcontrib>Ariyasu, Ryo ; Horiike, Atsushi ; Yoshizawa, Takahiro ; Dotsu, Yosuke ; Koyama, Junji ; Saiki, Masafumi ; Sonoda, Tomoaki ; Nishikawa, Shingo ; Kitazono, Satoru ; Yanagitani, Noriko ; Nishio, Makoto</creatorcontrib><description>Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs.
Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected.
Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case.
Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms.</description><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11814</identifier><identifier>PMID: 28739711</identifier><language>eng</language><publisher>Greece</publisher><subject>Adrenal Insufficiency - chemically induced ; Adrenal Insufficiency - pathology ; Adrenocorticotropic Hormone - deficiency ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Carcinoma, Non-Small-Cell Lung - complications ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Drug-Related Side Effects and Adverse Reactions - pathology ; Humans ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - genetics ; T-Lymphocytes, Cytotoxic - drug effects ; T-Lymphocytes, Cytotoxic - pathology</subject><ispartof>Anticancer research, 2017-08, Vol.37 (8), p.4229-4232</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28739711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ariyasu, Ryo</creatorcontrib><creatorcontrib>Horiike, Atsushi</creatorcontrib><creatorcontrib>Yoshizawa, Takahiro</creatorcontrib><creatorcontrib>Dotsu, Yosuke</creatorcontrib><creatorcontrib>Koyama, Junji</creatorcontrib><creatorcontrib>Saiki, Masafumi</creatorcontrib><creatorcontrib>Sonoda, Tomoaki</creatorcontrib><creatorcontrib>Nishikawa, Shingo</creatorcontrib><creatorcontrib>Kitazono, Satoru</creatorcontrib><creatorcontrib>Yanagitani, Noriko</creatorcontrib><creatorcontrib>Nishio, Makoto</creatorcontrib><title>Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs.
Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected.
Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case.
Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms.</description><subject>Adrenal Insufficiency - chemically induced</subject><subject>Adrenal Insufficiency - pathology</subject><subject>Adrenocorticotropic Hormone - deficiency</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Carcinoma, Non-Small-Cell Lung - complications</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Drug-Related Side Effects and Adverse Reactions - pathology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>T-Lymphocytes, Cytotoxic - drug effects</subject><subject>T-Lymphocytes, Cytotoxic - pathology</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81OwzAQhC0kREvhAbigHLmkZO3Yjm9UpUClSiBUztHW2dCg_GEnh7w9RpTTSKvZmW8Yu4FkySHT4h7bobLYOvJLgAzSMzYHbSDWUiQzdun9V5IoZTJxwWY8PBgNMGcPq8JRi3W0bf1YlpWtqLVT9E41DlREQxetQm785rpPh00TTo-EwzGGaH8kh_10xc5LrD1dn3TBPp42-_VLvHt93q5Xu7iHFIbYqkCpNJANtQkP5RqtVlgIYWQhxUFKLlWiDBYohS7RpJnV_JeSU4alWLC7v9zedd8j-SFvKm-prrGlbvQ5GC4AJNcQrLcn63gIxHnvqgbdlP-vFj97QVdb</recordid><startdate>201708</startdate><enddate>201708</enddate><creator>Ariyasu, Ryo</creator><creator>Horiike, Atsushi</creator><creator>Yoshizawa, Takahiro</creator><creator>Dotsu, Yosuke</creator><creator>Koyama, Junji</creator><creator>Saiki, Masafumi</creator><creator>Sonoda, Tomoaki</creator><creator>Nishikawa, Shingo</creator><creator>Kitazono, Satoru</creator><creator>Yanagitani, Noriko</creator><creator>Nishio, Makoto</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201708</creationdate><title>Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy</title><author>Ariyasu, Ryo ; Horiike, Atsushi ; Yoshizawa, Takahiro ; Dotsu, Yosuke ; Koyama, Junji ; Saiki, Masafumi ; Sonoda, Tomoaki ; Nishikawa, Shingo ; Kitazono, Satoru ; Yanagitani, Noriko ; Nishio, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-c6218671ec711029717ac76ad3395d53b55256069ada537fa948c7239712e8af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenal Insufficiency - chemically induced</topic><topic>Adrenal Insufficiency - pathology</topic><topic>Adrenocorticotropic Hormone - deficiency</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Carcinoma, Non-Small-Cell Lung - complications</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Drug-Related Side Effects and Adverse Reactions - pathology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>T-Lymphocytes, Cytotoxic - drug effects</topic><topic>T-Lymphocytes, Cytotoxic - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ariyasu, Ryo</creatorcontrib><creatorcontrib>Horiike, Atsushi</creatorcontrib><creatorcontrib>Yoshizawa, Takahiro</creatorcontrib><creatorcontrib>Dotsu, Yosuke</creatorcontrib><creatorcontrib>Koyama, Junji</creatorcontrib><creatorcontrib>Saiki, Masafumi</creatorcontrib><creatorcontrib>Sonoda, Tomoaki</creatorcontrib><creatorcontrib>Nishikawa, Shingo</creatorcontrib><creatorcontrib>Kitazono, Satoru</creatorcontrib><creatorcontrib>Yanagitani, Noriko</creatorcontrib><creatorcontrib>Nishio, Makoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ariyasu, Ryo</au><au>Horiike, Atsushi</au><au>Yoshizawa, Takahiro</au><au>Dotsu, Yosuke</au><au>Koyama, Junji</au><au>Saiki, Masafumi</au><au>Sonoda, Tomoaki</au><au>Nishikawa, Shingo</au><au>Kitazono, Satoru</au><au>Yanagitani, Noriko</au><au>Nishio, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2017-08</date><risdate>2017</risdate><volume>37</volume><issue>8</issue><spage>4229</spage><epage>4232</epage><pages>4229-4232</pages><eissn>1791-7530</eissn><abstract>Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs.
Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected.
Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case.
Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms.</abstract><cop>Greece</cop><pmid>28739711</pmid><doi>10.21873/anticanres.11814</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2017-08, Vol.37 (8), p.4229-4232 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1923115271 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenal Insufficiency - chemically induced Adrenal Insufficiency - pathology Adrenocorticotropic Hormone - deficiency Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Drug-Related Side Effects and Adverse Reactions - pathology Humans Male Middle Aged Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics T-Lymphocytes, Cytotoxic - drug effects T-Lymphocytes, Cytotoxic - pathology |
| title | Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T04%3A46%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adrenal%20Insufficiency%20Related%20to%20Anti-Programmed%20Death-1%20Therapy&rft.jtitle=Anticancer%20research&rft.au=Ariyasu,%20Ryo&rft.date=2017-08&rft.volume=37&rft.issue=8&rft.spage=4229&rft.epage=4232&rft.pages=4229-4232&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11814&rft_dat=%3Cproquest_pubme%3E1923115271%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1923115271&rft_id=info:pmid/28739711&rfr_iscdi=true |